RxDoctor Payments Data

Noor Alaina

Family · Plano, TXNPI 1518317304

Payments from drug & device makers

$8,644in general payments, 2019–2025

Across 432 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$885
  • Mannkind Corporation$879
  • Xeris Pharmaceuticals, Inc.$687
  • Medtronic$589
  • Corcept Therapeutics$576
  • Amgen$567
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,620100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,644 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$29,735
Medicare patients
161
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$239,107
MounjaroTirzepatide156$191,203
JardianceEmpagliflozin72$87,755
Tresiba Flextouch U-200Insulin Degludec48$52,074
Soliqua 100-33Insulin Glargine/Lixisenatide30$48,338
TrulicityDulaglutide33$44,053
Synjardy XrEmpagliflozin/Metformin Hcl18$34,149
RybelsusSemaglutide14$28,572
Tresiba Flextouch U-100Insulin Degludec34$27,777
Novolog FlexpenInsulin Aspart50$11,747
Nano 2nd Gen Pen NeedlePen Needle, Diabetic57$8,115
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,104
NovologInsulin Aspart16$5,386
Insulin Lispro Kwikpen U-100Insulin Lispro14$5,305
SynthroidLevothyroxine Sodium46$5,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$520$273,065165 claims
Lilly USA, LLCMounjaro, Trulicity$386$235,256189 claims
Boehringer IngelheimJardiance, Synjardy Xr$221$121,90490 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$411$48,33830 claims
AbbVieSynthroid$85$5,29846 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$75$2,855124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →